Earnings Releases·Nov 5, 2026, 4:08 PM ET

Sana Biotechnology — Third Quarter 2026 Earnings Summary

**Financial Performance:** The company reported a net income of $20.4 million ($0.07/share) for Q3 2026, a significant turnaround from a $42.2 million loss in the prior year period, driven largely by $63.4 million in non-cash gains; cash and equivalents decreased to $121.7 million as of September 30, 2026.
**Guidance and Runway:** Management expects to file an IND for SC451 and initiate Phase 1/2 trials in 2026, with first-in-human SG293 data anticipated in H1 2027, while the current cash position supports operations into mid-2027.
**Strategic Milestones:** Key developments include a follow-up NEJM publication on 14-month UP421 durability data without immunosuppression, preclinical SG293 data presented at ASGCT 2026, and an August 2026 amendment to the Cobalt acquisition agreement restructuring contingent consideration triggers.
**Capital and Operations:** Net proceeds from equity financings totaled $93.3 million in Q3 2026, and the company recorded no long-lived asset impairments in the nine months ended September 30, 2026, following a $44.6 million impairment in the prior year related to the suspended Bothell facility.